Skip to main content
. Author manuscript; available in PMC: 2012 Oct 17.
Published in final edited form as: J Cell Physiol. 2011 Sep;226(9):2438–2447. doi: 10.1002/jcp.22593

Fig. 9.

Fig. 9

CF102 inhibited the development of Hep-3B tumors in a xenograft model. Hep-3B cells were injected subcutaneously into the flank of balb/c nude mice. Oral treatment with CF102 (100 μg/kg, three times per day) was initiated when the tumor reached ~50–100 mm3 in size and lasted until study termination. A: CF102 treatment inhibited tumor growth in comparison to the vehicle-treated group. B,C: At the end of the study an inhibition of 46% in tumor volume was observed in the CF102-treated group (P < 0.05).